Diphenylpyraline | hsa00030 | Pentose phosphate pathway | 3.06E-04 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | |
Diphenylpyraline | hsa00052 | Galactose metabolism | 1.03E-02 | 2 | P06280, O43451 | GLA, MGAM | More | |
Diphenylpyraline | hsa00053 | Ascorbate and aldarate metabolism | 4.93E-02 | 1 | P14550 | AKR1A1 | More | |
Diphenylpyraline | hsa00190 | Oxidative phosphorylation | 1.03E-05 | 3 | Q16718, Q13488, O14521 | NDUFA5, TCIRG1, SDHD | More | |
Diphenylpyraline | hsa00500 | Starch and sucrose metabolism | 1.67E-02 | 2 | O43451, P06737 | MGAM, PYGL | More | |
Diphenylpyraline | hsa00565 | Ether lipid metabolism | 4.93E-02 | 1 | Q8N661 | TMEM86B | More | |
Diphenylpyraline | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | |
Diphenylpyraline | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | |
Diphenylpyraline | hsa00600 | Sphingolipid metabolism | 3.76E-02 | 1 | P15289 | ARSA | More | |
Diphenylpyraline | hsa00604 | Glycosphingolipid biosynthesis - ganglio series | 2.87E-03 | 3 | P06865, O15466, Q9H4F1 | HEXA, ST8SIA5, ST6GALNAC4 | More | |
Diphenylpyraline | hsa00640 | Propanoate metabolism | 3.83E-02 | 2 | Q02252, Q9P2R7 | ALDH6A1, SUCLA2 | More | |
Diphenylpyraline | hsa00730 | Thiamine metabolism | 5.29E-03 | 2 | P05186, P24666 | ALPL, ACP1 | More | |
Diphenylpyraline | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | |
Diphenylpyraline | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | |
Diphenylpyraline | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | |
Diphenylpyraline | hsa00983 | Drug metabolism - other enzymes | 2.44E-02 | 2 | P32320, P05164 | CDA, MPO | More | |
Diphenylpyraline | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | |
Diphenylpyraline | hsa01230 | Biosynthesis of amino acids | 2.60E-02 | 3 | P51854, P60891, P37837 | TKTL1, PRPS1, TALDO1 | More | |
Diphenylpyraline | hsa01240 | Biosynthesis of cofactors | 2.52E-02 | 2 | Q9BQB6, P14550 | VKORC1, AKR1A1 | More | |
Diphenylpyraline | hsa01521 | EGFR tyrosine kinase inhibitor resistance | 1.82E-02 | 1 | P08069 | IGF1R | More | |
Diphenylpyraline | hsa01522 | Endocrine resistance | 8.11E-03 | 3 | P04637, P42773, P08069 | TP53, CDKN2C, IGF1R | More | |
Diphenylpyraline | hsa01523 | Antifolate resistance | 3.80E-02 | 2 | Q92820, P04818 | GGH, TYMS | More | |
Diphenylpyraline | hsa02010 | ABC transporters | 1.66E-04 | 3 | P45844, P08183, Q8IZY2 | ABCG1, ABCB1, ABCA7 | More | |
Diphenylpyraline | hsa03013 | RNA transport | 2.99E-02 | 4 | P38919, P37198, P35658, P55884 | EIF4A3, NUP62, NUP214, EIF3B | More | |
Diphenylpyraline | hsa03020 | RNA polymerase | 9.86E-07 | 2 | Q9GZM3, P52435 | POLR2J2, POLR2J | More | |
Diphenylpyraline | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | |
Diphenylpyraline | hsa03030 | DNA replication | 5.00E-02 | 1 | P27694 | RPA1 | More | |
Diphenylpyraline | hsa03050 | Proteasome | 1.21E-02 | 1 | P28074 | PSMB5 | More | |
Diphenylpyraline | hsa03410 | Base excision repair | 2.52E-02 | 2 | P49005, P29372 | POLD2, MPG | More | |
Diphenylpyraline | hsa03430 | Mismatch repair | 4.38E-02 | 1 | P20585 | MSH3 | More | |
Diphenylpyraline | hsa04010 | MAPK signaling pathway | 1.23E-03 | 3 | P08069, Q9H2K8, Q12933 | IGF1R, TAOK3, TRAF2 | More | |
Diphenylpyraline | hsa04014 | Ras signaling pathway | 3.65E-02 | 1 | P08069 | IGF1R | More | |
Diphenylpyraline | hsa04015 | Rap1 signaling pathway | 5.18E-04 | 3 | P08069, P06213, O00522 | IGF1R, INSR, KRIT1 | More | |
Diphenylpyraline | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 4.48E-02 | 5 | P09341, P19875, P25024, P25025, P14784 | CXCL1, CXCL2, CXCR1, CXCR2, IL2RB | More | |
Diphenylpyraline | hsa04062 | Chemokine signaling pathway | 1.83E-02 | 8 | P25024, P25025, P09341, P19875, P42338, P19174, P63218, P50151 | CXCR1, CXCR2, CXCL1, CXCL2, PIK3CB, PLCG1, GNG5, GNG10 | More | |
Diphenylpyraline | hsa04064 | NF-kappa B signaling pathway | 2.49E-03 | 13 | P10415, Q13489, P14778, P29965, P19174, Q04759, Q9UDY8, P06239, Q8WV28, Q13315, P09341, P19875, Q06643 | BCL2, BIRC3, IL1R1, CD40LG, PLCG1, PRKCQ, MALT1, LCK, BLNK, ATM, CXCL1, CXCL2, LTB | More | |
Diphenylpyraline | hsa04066 | HIF-1 signaling pathway | 2.16E-02 | 1 | P08069 | IGF1R | More | |
Diphenylpyraline | hsa04068 | FoxO signaling pathway | 1.99E-02 | 1 | P08069 | IGF1R | More | |
Diphenylpyraline | hsa04070 | Phosphatidylinositol signaling system | 3.47E-02 | 4 | P0DP23, Q14643, P23743, P17252 | CALM1, ITPR1, DGKA, PRKCA | More | |
Diphenylpyraline | hsa04071 | Sphingolipid signaling pathway | 9.77E-06 | 10 | P17252, P21453, Q9H228, P01375, Q13362, Q9BX95, P10415, Q9UQC2, Q12933, Q02156 | PRKCA, S1PR1, EDG8, TNF, PPP2R5C, SGPP1, BCL2, GAB2, TRAF2, PRKCE | More | |
Diphenylpyraline | hsa04072 | Phospholipase D signaling pathway | 4.48E-02 | 5 | P42338, P43657, P25024, P25025, P19174 | PIK3CB, P2RY5, CXCR1, CXCR2, PLCG1 | More | |
Diphenylpyraline | hsa04080 | Neuroactive ligand-receptor interaction | 1.97E-02 | 5 | P28472, P21453, Q9H228, P21730, P07550 | GABRB3, S1PR1, EDG8, C5AR1, ADRB2 | More | |
Diphenylpyraline | hsa04110 | Cell cycle | 2.75E-04 | 9 | P30260, P06493, O75293, P04637, P49918, P30304, P33981, P42773, P01106 | CDC27, CDK1, GADD45B, TP53, CDKN1C, CDC25A, TTK, CDKN2C, MYC | More | |
Diphenylpyraline | hsa04114 | Oocyte meiosis | 2.99E-02 | 1 | P08069 | IGF1R | More | |
Diphenylpyraline | hsa04120 | Ubiquitin mediated proteolysis | 4.81E-03 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | |
Diphenylpyraline | hsa04140 | Autophagy - animal | 2.82E-02 | 1 | P08069 | IGF1R | More | |
Diphenylpyraline | hsa04145 | Phagosome | 1.59E-03 | 7 | Q15080, P14598, Q13509, P68371, Q13488, O60603, P13765 | NCF4, NCF1, TUBB3, TUBB2C, TCIRG1, TLR2, HLA-DOB | More | |
Diphenylpyraline | hsa04150 | mTOR signaling pathway | 2.32E-02 | 1 | P08069 | IGF1R | More | |
Diphenylpyraline | hsa04151 | PI3K-Akt signaling pathway | 7.73E-03 | 12 | P25116, P04637, P49767, Q13362, P62873, P16144, O60603, P01568, P10415, P17252, Q96BR1, P56279 | F2R, TP53, VEGFC, PPP2R5C, GNB1, ITGB4, TLR2, IFNA21, BCL2, PRKCA, SGK3, TCL1A | More | |
Diphenylpyraline | hsa04152 | AMPK signaling pathway | 1.99E-02 | 1 | P08069 | IGF1R | More | |
Diphenylpyraline | hsa04210 | Apoptosis | 3.58E-02 | 4 | O76075, P01375, Q9NR28, Q16548 | DFFB, TNF, DIABLO, BCL2A1 | More | |
Diphenylpyraline | hsa04211 | Longevity regulating pathway | 2.16E-02 | 1 | P08069 | IGF1R | More | |
Diphenylpyraline | hsa04213 | Longevity regulating pathway - multiple species | 1.14E-03 | 5 | P42338, P08069, Q9Y4H2, P11142, Q13547 | PIK3CB, IGF1R, IRS2, HSPA8, HDAC1 | More | |
Diphenylpyraline | hsa04217 | Necroptosis | 7.46E-06 | 13 | P01375, P01568, P48023, Q13489, P42224, Q14765, P08238, Q6FI13, Q99878, Q93077, P10415, O43633, Q08752 | TNF, IFNA21, FASLG, BIRC3, STAT1, STAT4, HSP90AB1, H2AC18; H2AC19, H2AC14, HIST1H2AC, BCL2, CHMP2A, PPID | More | |
Diphenylpyraline | hsa04218 | Cellular senescence | 4.79E-02 | 4 | P01106, O75293, P30304, P06493 | MYC, GADD45B, CDC25A, CDK1 | More | |
Diphenylpyraline | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.31E-03 | 8 | P09493, P07550, P22694, P18848, Q13362, P0DP23, P17252, P10415 | TPM1, ADRB2, PRKACB, ATF4, PPP2R5C, CALM1, PRKCA, BCL2 | More | |
Diphenylpyraline | hsa04330 | Notch signaling pathway | 2.77E-02 | 2 | Q92542, P49768 | NCSTN, PSEN1 | More | |
Diphenylpyraline | hsa04340 | Hedgehog signaling pathway | 3.32E-02 | 2 | P49841, P22694 | GSK3B, PRKACB | More | |
Diphenylpyraline | hsa04510 | Focal adhesion | 3.48E-02 | 1 | P08069 | IGF1R | More | |
Diphenylpyraline | hsa04514 | Cell adhesion molecules | 1.22E-02 | 2 | P23229, P30511 | ITGA6, HLA-F | More | |
Diphenylpyraline | hsa04520 | Adherens junction | 8.29E-03 | 1 | P08069 | IGF1R | More | |
Diphenylpyraline | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | |
Diphenylpyraline | hsa04540 | Gap junction | 1.29E-02 | 4 | P17252, Q13509, P68371, Q14643 | PRKCA, TUBB3, TUBB2C, ITPR1 | More | |
Diphenylpyraline | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 1.99E-02 | 1 | P08069 | IGF1R | More | |
Diphenylpyraline | hsa04610 | Complement and coagulation cascades | 1.15E-08 | 1 | P0C0L4 | C4A | More | |
Diphenylpyraline | hsa04612 | Antigen processing and presentation | 1.07E-03 | 6 | Q14953, P26715, P26717, Q13241, P01732, P01375 | KIR2DS5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | |
Diphenylpyraline | hsa04613 | Neutrophil extracellular trap formation | 6.17E-06 | 18 | P17252, P11215, O60603, P08246, Q13547, P04908, Q6FI13, Q93077, P58876, P62807, Q16778, O60814, P68431, P14598, Q15080, P21462, O43315, Q16539 | PRKCA, ITGAM, TLR2, ELA2, HDAC1, H2AC4; H2AC8, H2AC18; H2AC19, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF1, NCF4, FPR1, AQP9, MAPK14 | More | |
Diphenylpyraline | hsa04622 | RIG-I-like receptor signaling pathway | 2.47E-02 | 1 | Q12933 | TRAF2 | More | |
Diphenylpyraline | hsa04623 | Cytosolic DNA-sensing pathway | 3.15E-02 | 2 | P01568, P25963 | IFNA21, NFKBIA | More | |
Diphenylpyraline | hsa04640 | Hematopoietic cell lineage | 1.54E-03 | 9 | P21926, P14778, P27930, P11215, P25063, P07766, P01732, P01730, P09564 | CD9, IL1R1, IL1R2, ITGAM, CD24, CD3E, CD8A, CD4, CD7 | More | |
Diphenylpyraline | hsa04650 | Natural killer cell mediated cytotoxicity | 5.49E-06 | 12 | P19174, P01375, P06239, O60880, P20963, P42338, Q13241, P26718, O14931, P26717, Q14953, P26715 | PLCG1, TNF, LCK, SH2D1A, CD247, PIK3CB, KLRD1, KLRK1, NCR3, KLRC2, KIR2DS5, KLRC1 | More | |
Diphenylpyraline | hsa04657 | IL-17 signaling pathway | 2.10E-03 | 5 | P49841, P19875, P14780, P80188, P01375 | GSK3B, CXCL2, MMP9, LCN2, TNF | More | |
Diphenylpyraline | hsa04658 | Th1 and Th2 cell differentiation | 2.21E-04 | 8 | Q04759, P07766, P20963, P19174, P06239, Q9UL17, P14784, Q13761 | PRKCQ, CD3E, CD247, PLCG1, LCK, TBX21, IL2RB, RUNX3 | More | |
Diphenylpyraline | hsa04659 | Th17 cell differentiation | 1.25E-03 | 8 | Q04759, P19174, P06239, P14784, P14778, Q9UL17, P07766, P20963 | PRKCQ, PLCG1, LCK, IL2RB, IL1R1, TBX21, CD3E, CD247 | More | |
Diphenylpyraline | hsa04660 | T cell receptor signaling pathway | 3.37E-03 | 8 | Q04759, P42338, P19174, P07766, P20963, P01732, Q13191, P06239 | PRKCQ, PIK3CB, PLCG1, CD3E, CD247, CD8A, CBLB, LCK | More | |
Diphenylpyraline | hsa04668 | TNF signaling pathway | 3.55E-02 | 4 | P01375, P18848, P19875, P14780 | TNF, ATF4, CXCL2, MMP9 | More | |
Diphenylpyraline | hsa04672 | Intestinal immune network for IgA production | 3.76E-03 | 3 | P29965, P10747, P13765 | CD40LG, CD28, HLA-DOB | More | |
Diphenylpyraline | hsa04713 | Circadian entrainment | 2.60E-02 | 4 | P0DP23, P17252, P62873, Q14643 | CALM1, PRKCA, GNB1, ITPR1 | More | |
Diphenylpyraline | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | |
Diphenylpyraline | hsa04720 | Long-term potentiation | 3.89E-02 | 3 | P17252, P0DP23, Q14643 | PRKCA, CALM1, ITPR1 | More | |
Diphenylpyraline | hsa04721 | Synaptic vesicle cycle | 3.15E-02 | 2 | Q13488, P31645 | TCIRG1, SLC6A4 | More | |
Diphenylpyraline | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | |
Diphenylpyraline | hsa04723 | Retrograde endocannabinoid signaling | 1.88E-02 | 4 | Q14643, P17252, P62873, Q16718 | ITPR1, PRKCA, GNB1, NDUFA5 | More | |
Diphenylpyraline | hsa04725 | Cholinergic synapse | 1.88E-02 | 4 | Q14643, P17252, P62873, P10415 | ITPR1, PRKCA, GNB1, BCL2 | More | |
Diphenylpyraline | hsa04728 | Dopaminergic synapse | 3.55E-02 | 5 | Q14643, P17252, P62873, Q13362, P0DP23 | ITPR1, PRKCA, GNB1, PPP2R5C, CALM1 | More | |
Diphenylpyraline | hsa04730 | Long-term depression | 3.01E-03 | 2 | Q14344, P08069 | GNA13, IGF1R | More | |
Diphenylpyraline | hsa04744 | Phototransduction | 1.02E-02 | 2 | P62873, P0DP23 | GNB1, CALM1 | More | |
Diphenylpyraline | hsa04750 | Inflammatory mediator regulation of TRP channels | 7.24E-03 | 5 | P14778, P19174, P42338, P24723, Q04759 | IL1R1, PLCG1, PIK3CB, PRKCH, PRKCQ | More | |
Diphenylpyraline | hsa04810 | Regulation of actin cytoskeleton | 2.68E-02 | 2 | P23229, Q14344 | ITGA6, GNA13 | More | |
Diphenylpyraline | hsa04910 | Insulin signaling pathway | 2.35E-02 | 3 | P22694, P06737, P49841 | PRKACB, PYGL, GSK3B | More | |
Diphenylpyraline | hsa04912 | GnRH signaling pathway | 3.89E-02 | 3 | P17252, Q14643, P0DP23 | PRKCA, ITPR1, CALM1 | More | |
Diphenylpyraline | hsa04913 | Ovarian steroidogenesis | 5.67E-04 | 4 | P42330, P22694, P06213, P08069 | AKR1C3, PRKACB, INSR, IGF1R | More | |
Diphenylpyraline | hsa04914 | Progesterone-mediated oocyte maturation | 2.16E-02 | 1 | P08069 | IGF1R | More | |
Diphenylpyraline | hsa04919 | Thyroid hormone signaling pathway | 7.11E-03 | 4 | P49841, P22694, O60244, Q9NVC6 | GSK3B, PRKACB, MED14, MED17 | More | |
Diphenylpyraline | hsa04922 | Glucagon signaling pathway | 3.47E-02 | 4 | Q12778, Q13370, P0DP23, Q14643 | FOXO1, PDE3B, CALM1, ITPR1 | More | |
Diphenylpyraline | hsa04923 | Regulation of lipolysis in adipocytes | 4.24E-03 | 4 | P07550, P06213, P42338, Q9Y4H2 | ADRB2, INSR, PIK3CB, IRS2 | More | |
Diphenylpyraline | hsa04924 | Renin secretion | 7.38E-04 | 5 | P22694, P07550, Q14643, Q13370, P0DP23 | PRKACB, ADRB2, ITPR1, PDE3B, CALM1 | More | |
Diphenylpyraline | hsa04926 | Relaxin signaling pathway | 2.41E-02 | 4 | P18848, P22694, P14780, P30679 | ATF4, PRKACB, MMP9, GNA15 | More | |
Diphenylpyraline | hsa04927 | Cortisol synthesis and secretion | 2.54E-02 | 2 | P18848, P22694 | ATF4, PRKACB | More | |
Diphenylpyraline | hsa04930 | Type II diabetes mellitus | 1.28E-03 | 2 | P06213, Q02156 | INSR, PRKCE | More | |
Diphenylpyraline | hsa04931 | Insulin resistance | 1.94E-02 | 3 | P01375, P49841, P06737 | TNF, GSK3B, PYGL | More | |
Diphenylpyraline | hsa04932 | Non-alcoholic fatty liver disease | 2.44E-03 | 5 | P01375, P49841, P48023, Q16718, O14521 | TNF, GSK3B, FASLG, NDUFA5, SDHD | More | |
Diphenylpyraline | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 1.27E-02 | 5 | P42224, P10415, Q12778, P49767, P17252 | STAT1, BCL2, FOXO1, VEGFC, PRKCA | More | |
Diphenylpyraline | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
Diphenylpyraline | hsa04960 | Aldosterone-regulated sodium reabsorption | 3.14E-02 | 1 | P06213 | INSR | More | |
Diphenylpyraline | hsa04964 | Proximal tubule bicarbonate reclamation | 2.17E-03 | 1 | P00918 | CA2 | More | |
Diphenylpyraline | hsa04966 | Collecting duct acid secretion | 5.21E-06 | 4 | Q13488, P02730, P00918, Q9Y666 | TCIRG1, SLC4A1, CA2, SLC12A7 | More | |
Diphenylpyraline | hsa04970 | Salivary secretion | 1.91E-02 | 3 | P07550, P22694, P49913 | ADRB2, PRKACB, CAMP | More | |
Diphenylpyraline | hsa04973 | Carbohydrate digestion and absorption | 1.29E-02 | 2 | O43451, P42338 | MGAM, PIK3CB | More | |
Diphenylpyraline | hsa04974 | Protein digestion and absorption | 2.47E-02 | 1 | Q7Z2H8 | SLC36A1 | More | |
Diphenylpyraline | hsa04976 | Bile secretion | 1.67E-03 | 3 | O43315, P22694, P08183 | AQP9, PRKACB, ABCB1 | More | |
Diphenylpyraline | hsa05010 | Alzheimer disease | 3.55E-02 | 7 | Q16718, O14521, Q14643, P0DP23, Q13509, P68371, Q08752 | NDUFA5, SDHD, ITPR1, CALM1, TUBB3, TUBB2C, PPID | More | |
Diphenylpyraline | hsa05012 | Parkinson disease | 2.25E-02 | 6 | Q16718, O14521, Q14643, P0DP23, Q13509, P68371 | NDUFA5, SDHD, ITPR1, CALM1, TUBB3, TUBB2C | More | |
Diphenylpyraline | hsa05016 | Huntington disease | 2.46E-05 | 3 | Q9GZM3, P52435, Q9NYC9 | POLR2J2, POLR2J, DNAH9 | More | |
Diphenylpyraline | hsa05017 | Spinocerebellar ataxia | 2.43E-02 | 1 | P28074 | PSMB5 | More | |
Diphenylpyraline | hsa05020 | Prion disease | 1.31E-03 | 9 | Q16718, O14521, Q14643, Q13509, P68371, P49841, P14598, Q15080, Q16539 | NDUFA5, SDHD, ITPR1, TUBB3, TUBB2C, GSK3B, NCF1, NCF4, MAPK14 | More | |
Diphenylpyraline | hsa05022 | Pathways of neurodegeneration - multiple diseases | 2.00E-04 | 12 | Q14643, Q13509, P68371, P49841, P10415, Q16718, O14521, Q13561, P17252, Q16539, Q08752, P0DP23 | ITPR1, TUBB3, TUBB2C, GSK3B, BCL2, NDUFA5, SDHD, DCTN2, PRKCA, MAPK14, PPID, CALM1 | More | |
Diphenylpyraline | hsa05031 | Amphetamine addiction | 4.32E-02 | 3 | P22694, P18848, Q13547 | PRKACB, ATF4, HDAC1 | More | |
Diphenylpyraline | hsa05034 | Alcoholism | 2.05E-05 | 7 | Q13547, Q93077, P58876, P62807, Q16778, O60814, P68431 | HDAC1, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
Diphenylpyraline | hsa05100 | Bacterial invasion of epithelial cells | 4.50E-02 | 1 | Q92529 | SHC3 | More | |
Diphenylpyraline | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 2.78E-03 | 5 | P09341, P19875, P19174, P25024, P25025 | CXCL1, CXCL2, PLCG1, CXCR1, CXCR2 | More | |
Diphenylpyraline | hsa05131 | Shigellosis | 3.33E-03 | 10 | Q12933, P68431, Q02156, Q9UDY8, Q14247, Q14643, Q12778, Q13315, P10415, Q08752 | TRAF2, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, PRKCE, MALT1, CTTN, ITPR1, FOXO1, ATM, BCL2, PPID | More | |
Diphenylpyraline | hsa05132 | Salmonella infection | 1.11E-02 | 8 | Q9UJU2, Q13489, P10415, O60603, Q9BQS8, Q13561, Q13509, P68371 | LEF1, BIRC3, BCL2, TLR2, FYCO1, DCTN2, TUBB3, TUBB2C | More | |
Diphenylpyraline | hsa05133 | Pertussis | 3.47E-04 | 1 | P0C0L4 | C4A | More | |
Diphenylpyraline | hsa05134 | Legionellosis | 1.29E-02 | 4 | P11215, P11142, P09341, P19875 | ITGAM, HSPA8, CXCL1, CXCL2 | More | |
Diphenylpyraline | hsa05140 | Leishmaniasis | 1.06E-04 | 7 | P14598, P42224, P13765, O60603, P25963, P29350, Q15080 | NCF1, STAT1, HLA-DOB, TLR2, NFKBIA, PTPN6, NCF4 | More | |
Diphenylpyraline | hsa05143 | African trypanosomiasis | 7.50E-04 | 4 | P01375, P69905, P68871, P48023 | TNF, HBA2, HBB, FASLG | More | |
Diphenylpyraline | hsa05144 | Malaria | 1.44E-03 | 5 | P69905, P68871, P01375, P35443, P26718 | HBA2, HBB, TNF, THBS4, KLRK1 | More | |
Diphenylpyraline | hsa05145 | Toxoplasmosis | 1.11E-02 | 6 | P10415, Q13489, P42224, P13765, O60603, P29965 | BCL2, BIRC3, STAT1, HLA-DOB, TLR2, CD40LG | More | |
Diphenylpyraline | hsa05146 | Amoebiasis | 2.05E-05 | 11 | P09341, P19875, P14778, P27930, P01375, P42338, P11215, P05089, P30679, P22694, P12814 | CXCL1, CXCL2, IL1R1, IL1R2, TNF, PIK3CB, ITGAM, ARG1, GNA15, PRKACB, ACTN1 | More | |
Diphenylpyraline | hsa05150 | Staphylococcus aureus infection | 1.16E-03 | 6 | P0C0L4, P13646, Q14532, P59665, P59666, P49913 | C4A, KRT13, KRT32, DEFA1; DEFA1B, DEFA3, CAMP | More | |
Diphenylpyraline | hsa05152 | Tuberculosis | 7.93E-04 | 8 | Q13488, P0DP23, P42224, O60603, P10415, P13765, P01568, Q9UDY8 | TCIRG1, CALM1, STAT1, TLR2, BCL2, HLA-DOB, IFNA21, MALT1 | More | |
Diphenylpyraline | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | |
Diphenylpyraline | hsa05163 | Human cytomegalovirus infection | 4.31E-02 | 2 | P30511, Q14344 | HLA-F, GNA13 | More | |
Diphenylpyraline | hsa05165 | Human papillomavirus infection | 3.10E-02 | 8 | P16144, Q05086, P01568, P42224, Q13488, Q13362, Q12778, Q13315 | ITGB4, UBE3A, IFNA21, STAT1, TCIRG1, PPP2R5C, FOXO1, ATM | More | |
Diphenylpyraline | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 4.73E-02 | 6 | P01568, P42224, P62873, Q14643, P0DP23, Q9UJU2 | IFNA21, STAT1, GNB1, ITPR1, CALM1, LEF1 | More | |
Diphenylpyraline | hsa05168 | Herpes simplex virus 1 infection | 6.00E-04 | 16 | P25963, P01568, Q05823, P42224, Q07955, Q01130, Q13243, Q13489, Q9Y2A4, Q13398, P51522, Q9HCX3, P17038, P52738, O75820, Q9UDV6 | NFKBIA, IFNA21, RNASEL, STAT1, SFRS1, SFRS2, SFRS5, BIRC3, ZNF443, ZNF211, ZNF83, ZNF304, ZNF43, ZNF140, ZNF189, ZNF212 | More | |
Diphenylpyraline | hsa05170 | Human immunodeficiency virus 1 infection | 4.67E-03 | 9 | P62873, P0DP23, P17252, Q14643, P01568, O60603, Q13315, P10415, Q9Y6Q5 | GNB1, CALM1, PRKCA, ITPR1, IFNA21, TLR2, ATM, BCL2, AP1M2 | More | |
Diphenylpyraline | hsa05200 | Pathways in cancer | 4.99E-02 | 12 | P42224, Q9UJU2, P17252, P14923, P10415, Q13489, P49767, Q12778, P25116, P62873, P0DP23, P01568 | STAT1, LEF1, PRKCA, JUP, BCL2, BIRC3, VEGFC, FOXO1, F2R, GNB1, CALM1, IFNA21 | More | |
Diphenylpyraline | hsa05202 | Transcriptional misregulation in cancer | 8.55E-04 | 5 | P27930, P11215, P08069, Q13547, P12980 | IL1R2, ITGAM, IGF1R, HDAC1, LYL1 | More | |
Diphenylpyraline | hsa05203 | Viral carcinogenesis | 1.22E-03 | 6 | Q13547, Q15283, P58876, P62807, Q16778, O60814 | HDAC1, RASA2, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12 | More | |
Diphenylpyraline | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | |
Diphenylpyraline | hsa05205 | Proteoglycans in cancer | 1.09E-02 | 6 | P14780, P01375, P08069, P23588, Q13635, P22694 | MMP9, TNF, IGF1R, EIF4B, PTCH1, PRKACB | More | |
Diphenylpyraline | hsa05214 | Glioma | 9.95E-03 | 1 | P08069 | IGF1R | More | |
Diphenylpyraline | hsa05215 | Prostate cancer | 1.33E-02 | 1 | P08069 | IGF1R | More | |
Diphenylpyraline | hsa05216 | Thyroid cancer | 3.80E-02 | 2 | P01106, O75293 | MYC, GADD45B | More | |
Diphenylpyraline | hsa05218 | Melanoma | 9.63E-04 | 4 | P08069, P09619, Q9GZP0, Q02750 | IGF1R, PDGFRB, PDGFD, MAP2K1 | More | |
Diphenylpyraline | hsa05223 | Non-small cell lung cancer | 1.39E-02 | 3 | P10826, Q9HC35, O75293 | RARB, EML4, GADD45B | More | |
Diphenylpyraline | hsa05224 | Breast cancer | 1.49E-02 | 1 | P08069 | IGF1R | More | |
Diphenylpyraline | hsa05225 | Hepatocellular carcinoma | 1.33E-02 | 1 | P08069 | IGF1R | More | |
Diphenylpyraline | hsa05231 | Choline metabolism in cancer | 9.39E-03 | 4 | Q02750, P09619, Q9GZP0, O15245 | MAP2K1, PDGFRB, PDGFD, SLC22A1 | More | |
Diphenylpyraline | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 2.99E-04 | 8 | P42338, P19174, P07766, P20963, P06239, Q04759, Q9HC35, P01730 | PIK3CB, PLCG1, CD3E, CD247, LCK, PRKCQ, EML4, CD4 | More | |
Diphenylpyraline | hsa05320 | Autoimmune thyroid disease | 1.27E-03 | 4 | P13765, P29965, P01568, P10747 | HLA-DOB, CD40LG, IFNA21, CD28 | More | |
Diphenylpyraline | hsa05321 | Inflammatory bowel disease | 1.91E-02 | 3 | P01375, Q14765, Q9UL17 | TNF, STAT4, TBX21 | More | |
Diphenylpyraline | hsa05322 | Systemic lupus erythematosus | 2.33E-07 | 12 | P08246, P09871, P10747, P13765, P29965, Q6FI13, Q93077, P58876, P62807, Q16778, O60814, P68431 | ELA2, C1S, CD28, HLA-DOB, CD40LG, H2AC18; H2AC19, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
Diphenylpyraline | hsa05323 | Rheumatoid arthritis | 1.29E-02 | 4 | P13765, Q13488, P10747, O60603 | HLA-DOB, TCIRG1, CD28, TLR2 | More | |
Diphenylpyraline | hsa05330 | Allograft rejection | 1.04E-03 | 5 | P13765, P29965, P48023, P10747, P01375 | HLA-DOB, CD40LG, FASLG, CD28, TNF | More | |
Diphenylpyraline | hsa05332 | Graft-versus-host disease | 7.27E-04 | 4 | P48023, P01375, P26715, Q13241 | FASLG, TNF, KLRC1, KLRD1 | More | |
Diphenylpyraline | hsa05340 | Primary immunodeficiency | 1.28E-03 | 4 | P01730, P11912, P07766, P06239 | CD4, CD79A, CD3E, LCK | More | |
Diphenylpyraline | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 6.71E-04 | 3 | Q8IZS8, P54284, P13612 | CACNA2D3, CACNB3, ITGA4 | More | |
Diphenylpyraline | hsa05414 | Dilated cardiomyopathy | 2.58E-03 | 4 | Q8IZS8, P54284, P13612, P26678 | CACNA2D3, CACNB3, ITGA4, PLN | More | |
Diphenylpyraline | hsa05415 | Diabetic cardiomyopathy | 5.60E-05 | 8 | P17252, P14598, Q15080, Q16718, O14521, Q16539, P49841, P04406 | PRKCA, NCF1, NCF4, NDUFA5, SDHD, MAPK14, GSK3B, GAPDH | More | |
Diphenylpyraline | hsa05416 | Viral myocarditis | 2.62E-02 | 3 | P13765, P29965, P10747 | HLA-DOB, CD40LG, CD28 | More | |